Cephalosporins Should Be the Preferred Oral Antibiotics for Empiric Treatment of Outpatient Acute Pyelonephritis
When treating suspected outpatient pyelonephritis, consider prioritizing a cephalosporin over fluoroquinolones or TMP-SMX unless local resistance patterns strongly dictate otherwise. This shift may improve stewardship while maintaining robust coverage for this common condition. Remember that the choice must balance efficacy against minimizing collateral damage from broad-spectrum agents.
This article addresses the ongoing challenge of selecting appropriate empiric oral antibiotics for managing acute pyelonephritis in the outpatient setting, a common and potentially serious ED presentation. While fluoroquinolones and TMP-SMX have historically been the go-to recommendations from major guidelines, this piece argues for a shift toward cephalosporins as the preferred first-line agent. The core goal remains ensuring adequate coverage to prevent severe sequelae like sepsis or acute kidney injury while simultaneously supporting antimicrobial stewardship efforts. Given the high incidence of pyelonephritis in the ED, optimizing oral therapy is key to preventing unnecessary escalation of care or treatment failure.